An mRNA vaccine candidate encoding H5HA clade 2.3.4.4b protects mice from clade 2.3.2.1a virus infection

Shiho Chiba; Maki Kiso; Shinya Yamada; Kazuhiko Someya; Yoshikuni Onodera; Aya Yamaguchi; Satoko Matsunaga; Ryuta Uraki; Kiyoko Iwatsuki-Horimoto; Seiya Yamayoshi; Fumihiko Takeshita; Yoshihiro Kawaoka

doi:10.1038/s41541-024-00988-9

npj Vaccines (Oct 2024)

An mRNA vaccine candidate encoding H5HA clade 2.3.4.4b protects mice from clade 2.3.2.1a virus infection

Shiho Chiba,
Maki Kiso,
Shinya Yamada,
Kazuhiko Someya,
Yoshikuni Onodera,
Aya Yamaguchi,
Satoko Matsunaga,
Ryuta Uraki,
Kiyoko Iwatsuki-Horimoto,
Seiya Yamayoshi,
Fumihiko Takeshita,
Yoshihiro Kawaoka

Affiliations

Shiho Chiba: Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), The University of Tokyo
Maki Kiso: Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), The University of Tokyo
Shinya Yamada: Vaccine Research Laboratories, Research Function, R&D Division, Daiichi Sankyo Co., Ltd
Kazuhiko Someya: Vaccine Research Laboratories, Research Function, R&D Division, Daiichi Sankyo Co., Ltd
Yoshikuni Onodera: Vaccine Research Laboratories, Research Function, R&D Division, Daiichi Sankyo Co., Ltd
Aya Yamaguchi: Vaccine Research Laboratories, Research Function, R&D Division, Daiichi Sankyo Co., Ltd
Satoko Matsunaga: Vaccine Research Laboratories, Research Function, R&D Division, Daiichi Sankyo Co., Ltd
Ryuta Uraki: Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), The University of Tokyo
Kiyoko Iwatsuki-Horimoto: Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), The University of Tokyo
Seiya Yamayoshi: Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), The University of Tokyo
Fumihiko Takeshita: Vaccine Research Laboratories, Research Function, R&D Division, Daiichi Sankyo Co., Ltd
Yoshihiro Kawaoka: Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), The University of Tokyo

DOI: https://doi.org/10.1038/s41541-024-00988-9
Journal volume & issue: Vol. 9, no. 1
pp. 1 – 5

Abstract

Read online

Abstract Highly pathogenic avian influenza (HPAI) H5 viruses from different clades have been circulating globally, threatening wild/domestic birds and mammals. Given frequent spillovers and high mortality among mammals, coupled with our inability to predict which clade of H5 virus has pandemic potential, cross-clade protective HPAI H5 vaccines are urgently needed. Here, we demonstrate the applicability of a lipid nanoparticle-based mRNA vaccine modality to induce cross-protective immunity against lethal HPAI virus infection.

Published in npj Vaccines

ISSN: 2059-0105 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy; Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.nature.com/npjvaccines/

About the journal